A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary Hypercholesterolemia
Latest Information Update: 25 Oct 2024
At a glance
- Drugs Ezetimibe/rosuvastatin (Primary) ; Amlodipine/candesartan-cilexetil; Candesartan cilexetil/rosuvastatin; Ezetimibe
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Acronyms HODO-2224
- Sponsors Hyundai Pharmaceutical
- 25 Oct 2024 New trial record